Spinal Muscle Atrophy (SMA) in a 5 Years Old Girl from Macedonia: Case Report
Stefan Bittmann *
Department of Pediatrics, Ped Mind Institute, Medical and Finance Center Epe, Hindenburgring 4, 48599 Gronau, Germany.
Elisabeth Luchter
Department of Pediatrics, Ped Mind Institute, Medical and Finance Center Epe, Hindenburgring 4, 48599 Gronau, Germany.
Lara Bittmann
Department of Pediatrics, Ped Mind Institute, Medical and Finance Center Epe, Hindenburgring 4, 48599 Gronau, Germany.
Aysel Shirinova
Department of Pediatrics, Ped Mind Institute, Medical and Finance Center Epe, Hindenburgring 4, 48599 Gronau, Germany.
*Author to whom correspondence should be addressed.
Abstract
Spinal muscular atrophies are inherited diseases in which nerve cells in the spinal cord and brainstem regress, causing progressive muscle weakness and wasting. There are five main types of spinal muscular atrophy, which are classified according to the severity of muscle weakness and wasting. Depending on the type, one may be confined to a wheelchair, and life expectancy may also be limited. Based on symptoms, the diagnosis can be proven through family history, muscle and nerve function studies, and blood tests to determine the location of the defective gene. Spinal muscular atrophies are usually inherited in an autosomal recessive manner. Thus, for a person to inherit the disease, two genes are necessary, one from each parent. The group of SMA disease in childhood can affect the brain and spinal cord as well as the peripheral nerves. We present a case of a 5 years old girl with spinal muscle atrophy and analyze the different new therapeutical options and future research in the field of spinal muscular atrophy in childhood.
Keywords: Spinal muscular atrophy (SMA), SMA-child-treatment, SMN complexes, nerve cells
How to Cite
Downloads
References
Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers. 2022 Aug 4;8(1):52. DOI: 10.1038/s41572-022-00380-8 PMID: 35927425.
D'Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011 Nov 2;6:71.
DOI: 10.1186/1750-1172-6-71 PMID: 22047105; PMCID: PMC3231874.
Schorling DC, Pechmann A, Kirschner J. Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care. J Neuromuscul Dis. 2020;7(1):1-13.
DOI: 10.3233/JND-190424 PMID: 31707373; PMCID: PMC7029319.
Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Endear Study Group. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2; 377(18):1723-1732.
DOI: 10.1056/NEJMoa1702752 PMID: 29091570.
Acsadi G, Crawford TO, Müller-Felber W, Shieh PB, Richardson R, Natarajan N, et al. Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study. Muscle Nerve. 2021 May;63(5):668-677.
DOI: 10.1002/mus.27187 Epub 2021 Feb 16. PMID: 33501671; PMCID: PMC8248061.
Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Cherish Study Group. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med. 2018 Feb 15;378(7):625-635.
DOI: 10.1056/NEJMoa1710504 PMID: 29443664.
Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Servais L, Xiong H, Zanoteli E, et al. Firefish Study Group. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022 Dec;21(12):1110-1119. DOI: 10.1016/S1474-4422(22)00339-8
Epub 2022 Oct 14. PMID: 36244364.
Mercuri E, Baranello G, Boespflug-Tanguy O, De Waele L, Goemans N, Kirschner J, et al. Sunfish Working Group. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment. Eur J Neurol. 2023 Jul;30(7): 1945-1956. DOI: 10.1111/ene.15499 Epub 2022 Aug 1. PMID: 35837793.
Rudnicki SA, Andrews JA, Duong T, Cockroft BM, Malik FI, Meng L, et al. Reldesemtiv in Patients with Spinal Muscular Atrophy: A Phase 2 Hypothesis-Generating Study. Neurotherapeutics. 2021 Apr;18(2):1127-1136.
Doi: 10.1007/s13311-020-01004-3. Epub 2021 Feb 23. Erratum in: Neurotherapeutics. 2021 Jul;18(3):2130.
PMID: 33624184; PMCID: PMC8423982.
Bonanno S, Giossi R, Zanin R, Porcelli V, Iannacone C, Baranello G, et al. Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: A randomized, placebo-controlled, crossover phase 2 trial. J Neurol. 2022 Nov;269(11): 5858-5867. DOI: 10.1007/s00415-022-11231-7 Epub 2022 Jun 28. PMID: 35763114; PMCID: PMC9243784.
Oskoui M, Day JW, Deconinck N, Mazzone ES, Nascimento A, Saito K, et al. Sunfish Working Group. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol. 2023 May;270(5): 2531-2546. DOI: 10.1007/s00415-023-11560-1 Epub 2023 Feb 3. Erratum in: J Neurol; 2023 Apr 18. PMID: 36735057; PMCID: PMC9897618.
Acsadi G, Crawford TO, Müller-Felber W, Shieh PB, Richardson R, Natarajan N, et al. Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study. Muscle Nerve. 2021 May;63(5):668-677.
DOI: 10.1002/mus.27187 Epub 2021 Feb 16. PMID: 33501671; PMCID: PMC8248061.
Darras BT, Crawford TO, Finkel RS, Mercuri E, De Vivo DC, Oskoui M, et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol. 2019 Apr 17;6(5):932-944.
DOI: 10.1002/acn3.779 PMID: 31139691; PMCID: PMC6530526.
Mercuri E, Baranello G, Boespflug-Tanguy O, De Waele L, Goemans N, Kirschner J, et al. Sunfish Working Group. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment. Eur J Neurol. 2023 Jul;30(7): 1945-1956.
DOI: 10.1111/ene.15499 Epub 2022 Aug 1. PMID: 35837793.
Kissel JT, Elsheikh B, King WM, Freimer M, Scott CB, Kolb SJ, et al. Project Cure Spinal Muscular Atrophy Investigators Network. SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve. 2014 Feb;49(2):187-92.
DOI: 10.1002/mus.23904 PMID: 23681940; PMCID: PMC3888833.
Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, Krosschell KJ, et al. Project Cure Spinal Muscular Atrophy Investigators Network. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One. 2010 Aug 19;5(8):e12140.
DOI: 10.1371/journal.pone.0012140 PMID: 20808854; PMCID: PMC2924376.
Ohmura T, Saeki S, Ogiwara K, Tobita K, Ling Y, Torii S. [Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza®)]. Nihon Yakurigaku Zasshi. Japanese. 2018;152(3):147-159.
DOI: 10.1254/fpj.152.147 PMID: 30185733.
Weaver MS, Hanna R, Hetzel S, Patterson K, Yuroff A, Sund S, Schultz M, Schroth M, Halanski MA. A Prospective, Crossover Survey Study of Child- and Proxy-Reported Quality of Life According to Spinal Muscular Atrophy Type and Medical Interventions. J Child Neurol. 2020 Apr; 35(5):322-330. DOI: 10.1177/0883073819900463 Epub 2020 Feb 3. PMID: 32009500.